IBD
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Current evidence for first-line advanced therapies in pediatric ulcerative colitis: a critical review.
Clinical takeawayInfliximab may be considered for biologic-naïve pediatric UC patients given its robust evidence base, but evidence for vedolizumab, ustekinumab, and selective IL-23 inhibitors remains limited, and individualized treatment selection is currently unsupported by sufficient evidence.
What it foundAnti-TNF therapy, particularly infliximab, has the most comprehensive prospective pediatric evidence for first-line advanced therapy in UC, but direct comparative studies in biologic-naïve pediatric patients are lacking.
ContextHighlights infliximab's evidence base while emphasizing the lack of direct comparative studies and insufficient evidence for individualized treatment selection in biologic-naïve pediatric UC patients.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Kakiuchi T · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗